^
    Back
    Association details:
    Biomarker:TP53 mutation
    Cancer:Ovarian Cancer
    Drug:Lynparza (olaparib) (PARP inhibitor) +
    Truqap (capivasertib) (AKT inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Cancer Discov
    Title:

    Phase I trial of the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib and AKT inhibitor capivasertib in patients with BRCA1/2 and non-BRCA1/2 mutant cancers

    Published date:
    06/12/2020
    Excerpt:
    ...while another patient with platinum-resistant germline BRCA2 mutant HGSOC with somatic TP53 mutation and somatic BRCA1 VUS achieved a GCIG CA-125 response and RECIST SD lasting 56 weeks.
    DOI:
    10.1158/2159-8290.CD-20-0163
    Trial ID:
    ComPAKT